


NEWSRELEASE

DELMEDICAINVESTMENTS October 31st 2006

Delmedica offers the private equity investor access to unique biotechnology opportunities that have the hallmarks of commercially successful ventures.



This strategic alliance offers Delmedica a significant interest in a company about to revolutionise a highly profitable industry sector.



New Partnership Agreement with Biotechnology Leader

The Directors of Delmedica Investments Limited (*'Delmedica'*) have secured a 'Strategic Investment Agreement' with Fortune Apex Development Limited (*'Fortune Apex'*).

'Fortune Apex' has the proprietary rights over a novel drug delivery platform which has already attracted keen interest from key global pharmaceutical companies.

More detailed information about 'Fortune Apex' Development is available at the web site:

www.fortuneapex.com

Delmedica's capital contribution as negotiated within the 'Strategic Investment Agreement' will enable 'Fortune Apex' to implement the agreed Business Plan and, in due course, Delmedica shareholders will realise exceptional benefits from this strategic alliance:

- Shareholders will receive an allocation of an equivalent number of 'Fortune Apex' shares as a dividend
- In the event of a trade sale of 'Fortune Apex' or its proprietary technology, Delmedica shareholders would profit accordingly

This is an important opportunity to participate in a company poised to deliver a highly desirable product to the worldwide pharmaceutical market.

Biotechnology has evolved into a robust industry with global revenues rising from \$22 billion in 2000 to over \$80 billion in 2005*. A strategic alliance with 'Fortune Apex' will build on Delmedica's commitment to offer shareholders access to the lucrative and substantial future of Biotechnology.

In order to receive regular updates from Fortune Apex Development, please log-in upon entry to the website.

*Source: Burrill & Company. Sep 2006

www.delmedicainvestments

DELMEDICA

9/F Hong Kong Jewellery Building, 178-180 Queens Road Central, Hong Kong